Corrigendum to “Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine” Experimental Hematology. 2022;111:50-65
Experimental Hematology · 2026-06 · 158 · 105407
DOI: 10.1016/j.exphem.2026.105407 ↗Kurz gefasst
Korrektur in der Zeitschrift Experimental Hematology, 2026-06. Verfasst von Pawan Upadhyay und 9 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
Kein Abstract verfügbar.
Autor:innen und Institutionen
- Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO.
- Department of Medicine, Washington University School of Medicine, St. Louis, MO.
- Department of Neurological Surgery, Washington University School of Medicine, St. Louis, MO.
- Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, MO. Electronic address: jwelch@wustl.edu.
Zitieren
APA
Upadhyay, P., Beales, J., Shah, N. M., Gruszczynska, A., Miller, C. A., Petti, A. A., Ramakrishnan, S. M., Link, D. C., Ley, T. J., & Welch, J. S. (2026). Corrigendum to “Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine” Experimental Hematology. 2022;111:50-65. Experimental Hematology, 158, 105407. https://doi.org/10.1016/j.exphem.2026.105407
Vancouver
Upadhyay P, Beales J, Shah NM, Gruszczynska A, Miller CA, Petti AA, et al. Corrigendum to “Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine” Experimental Hematology. 2022;111:50-65. Experimental Hematology. 2026;158:105407. doi:10.1016/j.exphem.2026.105407
BibTeX
@article{Upadhyay2026,
author = {Upadhyay, Pawan and Beales, Jeremy and Shah, Nakul M and Gruszczynska, Agata and Miller, Christopher A and Petti, Allegra A and Ramakrishnan, Sai Mukund and Link, Daniel C and Ley, Timothy J and Welch, John S},
title = {Corrigendum to “Recurrent Transcriptional Responses in AML and MDS patients Treated with Decitabine” Experimental Hematology. 2022;111:50-65},
journal = {Experimental Hematology},
year = {2026},
volume = {158},
pages = {105407},
doi = {10.1016/j.exphem.2026.105407}
}
EUVIMED